rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

IDEAYA Biosciences, Inc.

IDYA · Nasdaq

Health CareBiotechnologyJust started moving

IDYA stood above a rising 150-day average in 40 of the last 52 weekly readings, including each of the last 1 week. It is 3.7% above that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−12 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Just started moving
Weeks in an uptrend
1 in a row
Industry in uptrend
18% -12 in 4 wk
Insider buys, 12 months
$3.3M
Insider sales, 12 months
$1.7M
Officials’ trades on record
0
Institutions holding
267 (+27)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 40 of 52 weeks.

22 Apr – 21 Oct
16%27%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$831K$0$3.1MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months2
Buyers · sellers1 · 2
WhoDidSharesTraded
Yujiro S. HataPresident and CEOsold25,538at $37.396 Oct 2026filed 8 Oct 2026
Yujiro S. HataPresident and CEOsold800at $38.266 Oct 2026filed 8 Oct 2026
Briseno Andres RuizChief Accounting Officersold9,550at $40.017 Jul 2026filed 9 Jul 2026
Jeffrey SteinDirectorbought50,000at $32.962 Mar 2026filed 2 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders267+27 on the quarter
New · exited63 · 36
Reported value$3.7B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
FMR LLCadded · filed 13 Aug 202614,109,431$525.9M+937,328+7.1%
BlackRock, Inc.added · filed 7 Aug 20268,893,260$331.5M+451,127+5.3%
Jupiter Topco LLCnew · filed 14 Aug 20268,579,881$319.7M+8,579,881
Capital Research Global Investorsadded · filed 12 Aug 20265,344,701$199.2M+181,158+3.5%
BAKER BROS. ADVISORS LPadded · filed 14 Aug 20265,010,030$186.7M+1,063,515+26.9%
STATE STREET CORPadded · filed 7 Aug 20264,548,911$169.5M+767,744+20.3%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20264,132,646$154.0M+400,224+10.7%
Logos Global Management LPreduced · filed 14 Aug 20263,000,000$111.8M-450,000−13.0%
ADAGE CAPITAL PARTNERS GP, L.L.C.reduced · filed 14 Aug 20262,715,391$101.2M-108,109−3.8%
DEERFIELD MANAGEMENT COMPANY, L.P.added · filed 14 Aug 20262,714,503$101.2M+1,184,495+77.4%
31 Mar 2023 – 30 Jun 2026
107184261Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Yujiro S. Hata Company insiderPresident and CEO · last 6 Oct 20260 · 10
Briseno Andres Ruiz Company insiderChief Accounting Officer · last 7 Jul 20260 · 6
Catherine J. Mackey Company insiderDirector · last 16 Jun 20260 · 0
Jeffrey Stein Company insiderDirector · last 16 Jun 20261 · 0
Malcolm Garret Hampton Company insiderDirector · last 16 Jun 20260 · 0
Scott W. Morrison Company insiderDirector · last 16 Jun 20260 · 0
Terry J. Rosen Company insiderDirector · last 16 Jun 20260 · 0
Wendy L. Yarno Company insiderDirector · last 16 Jun 20260 · 0
Darrin Beaupre Company insiderChief Medical Officer · last 30 Jan 20260 · 0
Douglas B. Snyder Company insiderSVP, General Counsel · last 30 Jan 20260 · 0
Joshua Bleharski Company insiderChief Financial Officer · last 30 Jan 20260 · 0
Michael Anthony White Company insiderChief Scientific Officer · last 30 Jan 20260 · 1

Same industry

MRNA ModernaLeading+168%
ENTX Entera BioLeading+53%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-72.8%
Free cash flow marginFY 2025 · to 31 Dec 2025-33.6%
Return on capital employedFY 2025 · to 31 Dec 2025-15.2%
Research spendFY 2025 · to 31 Dec 2025144%
Share count trendFY 2025 · to 13 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$112.8M
Free cash flowFY 2025 · to 31 Dec 2025−$73.5M

Analyst forecasts

No analyst forecasts yet.